CVS - CVS Health Corporation

NYSE - NYSE Delayed price. Currency in USD
62.65
-1.68 (-2.61%)
At close: 4:02PM EST

62.25 -0.40 (-0.64%)
Pre-market: 5:10AM EST

Stock chart is not supported by your current browser
Previous close64.33
Open64.65
Bid61.20 x 1200
Ask63.79 x 1300
Day's range62.55 - 65.20
52-week range51.72 - 77.03
Volume16,474,942
Avg. volume6,716,890
Market cap81.706B
Beta (5Y monthly)0.90
PE ratio (TTM)12.33
EPS (TTM)5.08
Earnings date28 Apr 2020 - 03 May 2020
Forward dividend & yield2.00 (3.11%)
Ex-dividend date21 Jan 2020
1y target est84.25
  • Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS
    Zacks

    Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS

    Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS

  • Oscar Health unveils program for lower drug prices, including insulin
    Yahoo Finance

    Oscar Health unveils program for lower drug prices, including insulin

    Oscar Health is offering prescription drugs at rock-bottom prices, following the lead of other health care players responding to the public’s demand for lower costs.

  • One of Your Stock Investments is Being Acquired: Now What?
    Zacks

    One of Your Stock Investments is Being Acquired: Now What?

    One of your companies gets a buyout offer and the shares soar. There might be different strategies for traders and investors on what to do next.

  • CVS Health Corporation Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
    Simply Wall St.

    CVS Health Corporation Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

    As you might know, CVS Health Corporation (NYSE:CVS) recently reported its annual numbers. Results were roughly in...

  • Top Stock Analyst Reports for Apple, American Express & Starbucks
    Zacks

    Top Stock Analyst Reports for Apple, American Express & Starbucks

    Top Stock Analyst Reports for Apple, American Express & Starbucks

  • CVS Executive Shift Puts Company Veteran at Helm of Biggest Unit
    Bloomberg

    CVS Executive Shift Puts Company Veteran at Helm of Biggest Unit

    (Bloomberg) -- CVS Health Corp. shook up its senior management ranks, putting a company veteran in charge of its pharmacy-benefit management business, less than two years after bringing on a longtime pharmaceutical executive to run it.The company said in a statement Wednesday that Alan Lotvin had been named president of CVS Caremark, taking the reins from Derica Rice, who will depart CVS. Rice, a former Eli Lilly & Co. executive who joined the company in 2018, will remain through this month to help ensure a smooth transition.The move puts one of Chief Executive Officer Larry Merlo’s most trusted lieutenants at the helm of CVS’s largest division. Lotvin has been with CVS since 2012, and in recent years had been charged with transforming the company after it acquired Aetna for $67 billion in its largest-ever takeover.Rice’s departure had been in the works for “some time” before the announcement, Merlo said in an interview. Merlo said the role of CVS’s pharmacy-services business is changing and Lotvin has “deep experience” in the space.The change reflects “the deep and talented bench that’s resonant within CVS Health,” Merlo said. “Quite frankly, I think that’s the story here, the talent that’s resonant across the organization.”The Aetna deal was premised in part on the idea that CVS could transform its drugstores into centers where patients could receive basic care and pick up prescriptions, driving down health costs. But CVS shares have languished since the transaction closed in late 2018, with investors wary of the effects of political wrangling over drug prices, as well as the overall growth prospects of the combined company.Rice’s departure followed news last week that former Aetna CEO Mark Bertolini had stepped down from CVS’s board. Bertolini said he had offered to remain a director past his current term, but wasn’t renominated. And Kevin Hourican, who led CVS’s retail-pharmacy business, left last month to become CEO of food-service company Sysco. Hourican joined CVS in 2012 from Macy’s.Other notable Aetna alumni have also departed recently, including former Chief Technology Officer Claus Torp Jensen, who left for Memorial Sloan Kettering in October. But some of the insurer’s most visible leaders remain, including Karen Lynch, who is president of the business, and Rick Jelinek, who’s leading the integration. And CVS said Wednesday it promoted Aetna’s Jonathan Mayhew to executive vice president of transformation, a role previously occupied by Lotvin.“As you look at talent within the organization, the Aetna operating team is largely intact, so there has not been a large exodus of the company,” Merlo said. “I’m very pleased with how the two organizations and the culture of the organizations is coming together.”Shares of CVS were down 1.2% at $72.94 at 2:10 p.m. in New York.The company also projected better-than-expected revenue for the year and posted stronger-than-forecast fourth-quarter results. In an investor presentation, CVS said it expects 2020 revenue of $261.97 billion to $265.48 billion, above the average Wall Street forecast of $256.89 billion. The pharmacy-services business is expected to be a critical plank of that growth, with projected 2020 sales of $137.50 billion to $139.45 billion.To contact the reporter on this story: Angelica LaVito in New York at alavito@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • CVS profit beats estimates; will hold off on new major deals
    Reuters

    CVS profit beats estimates; will hold off on new major deals

    The company, which acquired health insurer Aetna for $69 billion in 2018, is not planning further major deals until it has completed the Aetna integration and reduced the debt load it took on, Chief Executive Larry Merlo told Reuters in an interview. Aetna revenue nearly tripled in the quarter from a year ago to $17.15 billion.

  • CVS Health (CVS) Q4 Earnings Top Estimates, Margins Improve
    Zacks

    CVS Health (CVS) Q4 Earnings Top Estimates, Margins Improve

    CVS Health (CVS) registers strong growth in Pharmacy Services, benefiting from the upside in specialty services.

  • The Federal Budget in Focus
    Zacks

    The Federal Budget in Focus

    The Federal Budget in Focus

  • Shopify, CVS Outperform in Q4, Plus COVID-19 Update
    Zacks

    Shopify, CVS Outperform in Q4, Plus COVID-19 Update

    Shopify (SHOP) impressed investors with a big beat on both top and bottom lines: 43 cents per share versus 23 cents expected, on $505.2 million which easily surpassed the Zacks consensus $482.3 million.

  • CVS Health (CVS) Surpasses Q4 Earnings and Revenue Estimates
    Zacks

    CVS Health (CVS) Surpasses Q4 Earnings and Revenue Estimates

    CVS Health (CVS) delivered earnings and revenue surprises of 2.98% and 4.16%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • CVS Health Corp Earnings, Revenue Beat in Q4
    Investing.com

    CVS Health Corp Earnings, Revenue Beat in Q4

    Investing.com - CVS Health Corp reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.

  • Powell testimony, Cisco earnings: What to know in markets Wednesday
    Yahoo Finance

    Powell testimony, Cisco earnings: What to know in markets Wednesday

    Federal Reserve Chairman Jay Powell heads to Capitol Hill for another day of testimony in front of Congress and Cisco reports earnings Wednesday.

  • Investing.com

    Day Ahead: Top 3 Things to Watch for Feb. 12

    Investing.com - Here are three things that could rock the markets tomorrow.

  • Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?
    Zacks

    Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?

    Expanded claims volume and better purchasing economics are expected to have aided CVS Health's (CVS) top line in Q4.

  • How Much Are CVS Health Corporation (NYSE:CVS) Insiders Spending On Buying Shares?
    Simply Wall St.

    How Much Are CVS Health Corporation (NYSE:CVS) Insiders Spending On Buying Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • CVS Health (CVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Zacks

    CVS Health (CVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • CVS Health (CVS) Gains But Lags Market: What You Should Know
    Zacks

    CVS Health (CVS) Gains But Lags Market: What You Should Know

    In the latest trading session, CVS Health (CVS) closed at $67.88, marking a +1.42% move from the previous day.

  • Pharmacies & Drug Stores Industry Outlook: Prospects Mixed
    Zacks

    Pharmacies & Drug Stores Industry Outlook: Prospects Mixed

    Pharmacies & Drug Stores Industry Outlook: Prospects Mixed

  • CVS Health (CVS) Dips More Than Broader Markets: What You Should Know
    Zacks

    CVS Health (CVS) Dips More Than Broader Markets: What You Should Know

    In the latest trading session, CVS Health (CVS) closed at $70.55, marking a -1.77% move from the previous day.

  • CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
    Zacks

    CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know

    CVS Health (CVS) closed at $73.53 in the latest trading session, marking a -0.65% move from the prior day.

  • Government run health care: A cost-saver or 'unfair competition'?
    Yahoo Finance

    Government run health care: A cost-saver or 'unfair competition'?

    Amid surging health care costs and acrimonious public debate, a new study found that a public-run system would save money over time.

  • Should CVS Health Corporation (NYSE:CVS) Be Part Of Your Dividend Portfolio?
    Simply Wall St.

    Should CVS Health Corporation (NYSE:CVS) Be Part Of Your Dividend Portfolio?

    Dividend paying stocks like CVS Health Corporation (NYSE:CVS) tend to be popular with investors, and for good reason...

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more